ARCA receives European Patent for bucindolol based treatment for heart failure ARCA biopharma.

Bristow, Chief and President Executive Officer of ARCA.. ARCA receives European Patent for bucindolol based treatment for heart failure ARCA biopharma, Inc. , a biopharmaceutical business developing genetically-targeted treatments for heart failure and other cardiovascular illnesses, today announced that the European Patent Office has released a patent on methods of treating heart failing patients with bucindolol predicated on genetic targeting. The patent entitled Methods for Treatment with Bucindolol Predicated on Genetic Targeting, provides security for this novel method of treating patients with heart failing in France, Germany, Netherlands, Switzerland/Liechtenstein, THE UK, Ireland, Luxembourg, Monaco, Spain, Sweden and Italy.I really believe in you!

Almost all heart attack patients receive angioplasty within 90 minutes to be admitted Almost all heart attack patients who require the emergency artery-opening method referred to as angioplasty are receiving it within 90 minutes of being admitted to the hospital, a marked improvement from five years back when most patients waited much longer for the life-saving procedure, according to a report by Yale School of Medicine researchers and their colleagues. Published in Circulation: Journal of American Heart Association, the five-year study is among the most comprehensive analyses of angioplasty timeliness.